Estrogen- and Progesterone-Receptor Status in ECOG 2197….pdfVIP

V O L U M E 2 6 N U M B E R 1 5 M A Y 2 0 2 0 0 8 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory Sunil S. Badve, Frederick L. Baehner, Robert P. Gray, Barrett H. Childs, Tara Maddala, Mei-Lan Liu, Steve C. Rowley, Steven Shak, Edith D. Perez, Lawrence J. Shulman, Silvana Martino, Nancy E. Davidson, George W. Sledge, Lori J. Goldstein, and Joseph A. Sparano From the Eastern Cooperative Oncol- A B S T R A C T ogy Group, Boston, MA; the University of California, San Francisco, San Fran- cisco, CA; Genomic Health Inc, Purpose Redwood City, CA; sanofi-aventis, Central and local laboratory concordance for hormone receptor measurement is therapeutically Bridgewater, NJ; North Central Cancer important. This study compares estrogen receptor (ER) and progesterone receptor (PR) measured Treatment Group, Rochester, MN; by local laboratory immunohistochemistry (IHC), central IHC, and central reverse-transcriptase Cancer and Leukemia Group B, polymerase chain reaction (RT-PCR) using a proprietary 21-gene assay. Chicago, IL; and the Southwest Oncol- ogy Group, San Antonio, TX. Patients and Methods Submitted August 12